What changed
📄 SALARIUS PHARMACEUTICALS, INC.
Salarius is a clinical-stage biopharmaceutical company focused on developing treatments for cancers with high unmet medical need caused by dysregulated gene expression. Its pipeline includes two small molecule drugs: SP-3164, a targeted protein degrader, and seclidemstat (SP-2577), a targeted protein inhibitor. The company is in the process of merging with Decoy Therapeutics, Inc. to integrate its assets and expand into peptide conjugate development.
Price range: $4.08
Key risk: The trading price of the shares of Salarius’ common stock could be highly volatile, and purchasers of Salarius’ common stock could incur substantial losses.
Why it matters
Salarius is a clinical-stage biopharmaceutical company focused on developing treatments for cancers with high unmet medical need caused by dysregulated gene expression. Its pipeline includes two small molecule drugs: SP-3164, a targeted protein degrader, and seclidemstat (SP-2577), a targeted protein inhibitor. The company is in the process of merging with Decoy Therapeutics, Inc. to integrate its assets and expand into peptide conjugate development.